Achilles therapeutics provides interim phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma including first patients dosed with enhanced host conditioning

– improved velos™ manufacturing process delivering higher cnet doses – – protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2h 2024 – – first three patients dosed in chiron and thetis with enhanced host chemo-conditioning, along with il-2 aligned to standard til therapy, show improved cnet persistence and engraftment – london, april 04, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim phase i/iia data on the use of clonal neoantigen reactive t cells (cnet) from the chiron study in advanced unresectable or metastatic non-small cell lung cancer (nsclc) and the thetis study in recurrent or metastatic malignant melanoma. the update includes data from 18 patients across chiron (n=12) and thetis (n=6) dosed since the previous interim update in december 2022, with two chiron patients and one thetis patient having received enhanced chemo-conditioning and il-2 dosing aligned to standard tumor infiltrating lymphocyte (til) therapy (enhanced host conditioning) in a new cohort c.
ACHL Ratings Summary
ACHL Quant Ranking